Dexketoprofen

CHEMBL75435 Phase 4 Approved Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
254.3 g/mol
LogP
3.1
Phase
4

The pharmacologically active S-enantiomer of the NSAID ketoprofen, used for short-term treatment of mild-to-moderate pain including musculoskeletal conditions, dysmenorrhea, and dental pain. Isolating the active enantiomer may provide an improved side-effect profile at lower doses.

Molecular Weight

254.2800 g/mol

LogP

3.10

TPSA

54.40 Ų

Lipinski RO5

Pass

Therapeutic Areas

Mechanism of Action

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

2D Structure

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1

InChI

InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)/t11-/m0/s1

Molecular Formula

C16H14O3

HBD / HBA

1 / 3

Rotatable Bonds

4

Heavy Atoms

19

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

The pharmacologically active S-enantiomer of the NSAID ketoprofen, used for short-term treatment of mild-to-moderate pain including musculoskeletal conditions, dysmenorrhea, and dental pain. Isolating the active enantiomer may provide an improved side-effect profile at lower doses.

Inhibits cyclooxygenase (COX-1 and/or COX-2) enzymes, reducing the synthesis of prostaglandins and thromboxanes from arachidonic acid. This produces anti-inflammatory, analgesic, and antipyretic effects.

Yes, Dexketoprofen is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL75435. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 667550. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.